Breast Cancer
Breast Cancer: Testing and Treatment ESR1 Mutations in Recurrent HR+ HER2-

Released: April 03, 2024

Expiration: July 30, 2024

Paolo Tarantino
Paolo Tarantino, MD

Activity

Progress
1
Course Completed

Breast Cancer: Testing and Treatment ESR1 Mutations in Recurrent HR+ HER2-

Key Takeaways:

  • Understand rationale and guidelines supporting ESR1 mutation testing in patients with HR+ HER2- recurrent breast cancer
  • Review updated clinical data and treatment options for patients with recurrent HR+ HER2- breast cancer and ESR1 mutations